HIV Vaccine Challenges: Mutation, Immune Evasion & Research Directions
Despite 40+ years, no effective HIV vaccine exists. Key barriers:
Major Scientific Hurdles
- Extreme genetic diversity: Error-prone RT → quasispecies; multiple clades (A–K), recombinants. Vaccine must cover global variants.
- No natural sterilizing immunity: No human clears HIV; no correlate of protection to mimic.
- Immune evasion: Glycan shield on Env, variable loops, Nef/Vpu downregulation of MHC-I, latency in reservoirs.
- Inadequate animal models: SIV/SHIV in macaques imperfectly mimics HIV pathogenesis.
- Complex envelope trimer: Metastable, conformationally masked conserved epitopes (CD4bs, V2 apex, MPER, fusion peptide).
- Immune tolerance/exhaustion: Chronic antigen → T-cell dysfunction.
Promising Strategies
- Germline-targeting immunogens: Prime bnAb precursors (e.g., VRC01-class, PGT121-class).
- mRNA platforms: Rapid iteration, native-like trimers (e.g., Moderna/IAVI trials).
- Mosaic/consensus sequences: Cover global diversity (Janssen Ad26.Mos4.HIV).
- T-cell vaccines: Target conserved internal proteins (Gag, Pol) for viral control.
- Broadly neutralizing antibodies (bnAbs): Passive infusion (VRC01, 3BNC117) + long-acting formulations.
Progress is incremental; combination approaches likely needed.
HIV & AIDS - Related Articles
- Promoting Equal Opportunities and Anti-Discrimination: A Practical Guide
- Early HIV Symptoms: Timing, Variability, and Importance of Testing
- SE‑44 RFID Technology: Specifications and Applications
- Mississippi HIV/AIDS Statistics 2021: Estimated Cases and AIDS Diagnoses
- HIV Testing Window Period: Why a Negative Result at 3 Months Is Usually Conclusive
- HIV and the Nervous System: Neurological Complications Explained
- HIV Survival Outside the Body: Debunking the “1‑Second” Myth
